In addition, preclinical data suggest that GLP-1 agonists may have anti-inflammatory, immunoregulatory, and chondroprotective effects, potentially benefiting OA patients. According to Wright, further analysis is necessary to understand if these medications can truly impact OA patients beyond pain management
In people with known thrombophilia or recent VTE, the decision to start Tirzepatide should include a careful risk-benefit discussion with a clinician
2007 Zhong ' -Am J Physiol, mRNA GIPR , GIP
Decreased appetite: This is technically a therapeutic effect, not a side effect, but it can feel extreme during the first few weeks at a new dose
Most GLP-1 agonists do not require dose adjustment for mild to moderate renal impairment, though specific agents have varying recommendations for severe impairment
The Glow Stack The Glow Stack combines multiple research compounds that are frequently discussed within skin, connective tissue, and cellular signalling research